Air Force Military Medical University, China Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2012
NCT01694823
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Air Force Military Medical University, China | Mei Shi | Shengqing Li | Tangdu Hospital of Air Force Military Medical University | The First Affiliated Hospital of the Air Force Medical Universtiy | The First Affiliated Hospital,the Air Force Medical University | The Second Affiliated Hospital of Air Force Military Medical University | Xijing Hospital Affiliated to Air Force Military Medical University | Xijing Hospital, Air Force Medical University of PLA | Xijing Hospital of Air Force Military Medical University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Joint Diseases (Phase 2)

Lung Neoplasms (Phase 3)

Osteochondritis (Phase 2)

Osteochondritis Dissecans (Phase 2)

Thromboembolism (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Venous Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 26